Literature DB >> 8967479

Glucose tolerance and insulin action in healthy centenarians.

G Paolisso1, A Gambardella, S Ammendola, A D'Amore, V Balbi, M Varricchio, F D'Onofrio.   

Abstract

Advancing age has been found to be associated with a decline in insulin action. Nevertheless, no study has been conducted in healthy centenarians. Our study investigates glucose tolerance and insulin action in centenarians. Fifty-two subjects were enrolled. The subjects were divided in three groups as follows: 1) adults (< 50 yr; n = 20);2) aged subjects (> 75 yr; n = 22); and 3) centenarians (> 100 yr; n = 14). Body composition was studied by bioimpedance analysis. In all subjects, an oral glucose tolerance test and euglycemic glucose clamp were performed. Centenarians have a lower fat-free mass (FFM) than aged subjects and adults, whereas fasting plasma glucose, triglycerides, free fatty acids, urea, and creatinine were not different in the groups studies. Centenarians had a 2-h plasma glucose concentration (6.0 +/- 0.2 mmol/l) that was lower than that in aged subjects (6.6 +/- 0.5 mmol/l, P < 0.05) but not different from adults [6.4 +/- 0.4 mmol/l, P = not significant (NS)]. During the clamp, plasma glucose and insulin concentrations were similar in the three groups. In these conditions, centenarians had a whole body glucose disposal (34.1 +/- 0.6 mumol.kg FFM-1.min 1) that was greater than that in aged subjects (23.3 +/- 0.5 mumol.kg FFM-1.min-1 P < 0.01) but not different from adults (34.6 +/- 0.5 mumol/kg x min, P = NS). In conclusion, our study demonstrates that centenarians compared with aged subjects had a preserved glucose tolerance and insulin action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8967479     DOI: 10.1152/ajpendo.1996.270.5.E890

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  37 in total

Review 1.  Hormonal regulation of longevity in mammals.

Authors:  Holly M Brown-Borg
Journal:  Ageing Res Rev       Date:  2007-02-20       Impact factor: 10.895

Review 2.  Healthspan and longevity can be extended by suppression of growth hormone signaling.

Authors:  Andrzej Bartke
Journal:  Mamm Genome       Date:  2016-02-24       Impact factor: 2.957

Review 3.  The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer.

Authors:  Vladimir N Anisimov; Andrzej Bartke
Journal:  Crit Rev Oncol Hematol       Date:  2013-02-21       Impact factor: 6.312

4.  Insulin, IGF-1 and longevity.

Authors:  Diana van Heemst
Journal:  Aging Dis       Date:  2010-08-26       Impact factor: 6.745

5.  Abdominal adiposity is a stronger predictor of insulin resistance than fitness among 50-95 year olds.

Authors:  Susan B Racette; Ellen M Evans; Edward P Weiss; James M Hagberg; John O Holloszy
Journal:  Diabetes Care       Date:  2006-03       Impact factor: 19.112

Review 6.  Somatotropic signaling: trade-offs between growth, reproductive development, and longevity.

Authors:  Andrzej Bartke; Liou Y Sun; Valter Longo
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

7.  Human insulin/IGF-1 and familial longevity at middle age.

Authors:  Maarten P Rozing; Rudi G J Westendorp; Marijke Frölich; Anton J M de Craen; Marian Beekman; Bastiaan T Heijmans; Simon P Mooijaart; Gerard-Jan Blauw; P Eline Slagboom; Diana van Heemst
Journal:  Aging (Albany NY)       Date:  2009-07-24       Impact factor: 5.682

Review 8.  Diabetes and altered glucose metabolism with aging.

Authors:  Rita Rastogi Kalyani; Josephine M Egan
Journal:  Endocrinol Metab Clin North Am       Date:  2013-03-22       Impact factor: 4.741

9.  Syntaxin 4 Overexpression Ameliorates Effects of Aging and High-Fat Diet on Glucose Control and Extends Lifespan.

Authors:  Eunjin Oh; Richard A Miller; Debbie C Thurmond
Journal:  Cell Metab       Date:  2015-09-01       Impact factor: 27.287

10.  Maternal protein restriction affects postnatal growth and the expression of key proteins involved in lifespan regulation in mice.

Authors:  Jian-Hua Chen; Malgorzata S Martin-Gronert; Jane Tarry-Adkins; Susan E Ozanne
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.